Q2 2026 Isofol Medical AB Earnings Call
Speaker #1: Quarter by quarter, we are moving closer to achieving our goal of establishing our politics screen as a key part of tomorrow's cancer treatment. Second quarter was no exception: the phase 1B study continues to progress, and we've seen a positive interim efficacy readouts and so far a favorable safety profile across all completed dose levels.
Speaker #1: On the back of this, we've moved directly to the highest dose in the dose escalation phase, and as this court is likely to be the last, we are approaching completion of phase 1B.
Speaker #1: On the regulatory front, we've received approvals for study enhancements and are adding additional partner hospitals and trial sites to accelerate patient recruitment in both phase 1 and 2.
Speaker #1: So we're now gearing up for a head start of phase 2, creating value through strong and focused clinical execution. So I'd like to thank all shareholders for being a part of our journey, and above all, my great coworkers, partners, and patients for making it happen.
